LEO Pharma’s Atopic Dermatitis Program Lags as PMDA Requests Japanese Data, but Growth Goal Intact

Stefan Sakurai, President, Japan Representative Director, LEO Pharma K.K. Danish dermatology powerhouse LEO Pharma A/S has seen a delay in the development of its atopic dermatitis treatment tralokinumab in Japan as it has been requested to submit additional data to...read more